The safety and efficacy of ClearifiRx and its active pharmaceutical ingredients in pregnant and nursing women has not been established.
Adapalene belongs to a class of medications known as retinoids. The use of systemic retinoids has been associated with birth defects such as embryo-fetal death, altered fetal growth, congenital malformations, and potential neurological deficits. Although the risk of teratogenesis due to topical exposure to adapalene and/or ClearifiRx is considered low, in general, the use of drugs in pregnancy should be minimized. ClearifiRx should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether topical application of ClearifiRx can result in sufficient systemic absorption to produce detectable quantities of desonide, hydroquinone, azelaic acid or adapalene in human milk. Because many drugs are secreted in human milk, caution should be exercised when ClearifiRx is used by nursing women. Care should be taken to avoid contact between the infant being nursed and ClearifiRx.